FIG 1.
Prevalence of NNRTI resistance-associated amino acid substitutions among first-line treatment failures. Sequences from 1,433 HIV-1 subtype C-infected patients failing first-line therapy with NNRTI resistance-associated mutations were obtained from the SATuRN (n = 766; light gray bars) and Stanford (n = 667; dark gray bars) databases. Amino acid substitutions are grouped according to prevalence: >10%, 5% to 10%, 1% to 5%, and <1%.